BioMelbourne Network Progressing BioIndustry

24th March, 2015 BioBriefing:
‘Building Biotechnology: Advances in chemical manufacturing’
IDT facility tour & BioBriefing More

Victorian BioPortal

Looking for Something?

The Victorian BioPortal is the largest online search engine for biotechnology in Victorian with over 2,000 individual listings.

Start your search now

BioMelbourne Network

The Building Global Bridges program provides grants of between $100,000 & $500,000 to Victorian life science companies to develop partnerships with Massachusetts companies in late stage life sciences R&D projects. The program helps Victorian innovation to accelerate, access expertise, develop skills & better reach global markets and international investors. Applications close 17 September 2013.

Building Global Bridges

Phosphagenics Decides to Sell BioElixia® Cosmetics Brand

25 February 2015.  Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), has put its branded cosmetics division, BioElixia®, up for sale to allow resources to be refocused on the Company’s core areas of strength. Phosphagenics has recently received a number of expressions of interest in purchasing its range of Personal Care products sold under the BioElixia® brand.  ... read more…

Industry Growth Centre Appointments

19 February 2015.   The Minister for Industry and Science, the Hon Ian Macfarlane MP, announced three of the five Chairs of the Industry Growth Centres on the 17 February 2015.   The announced Chairs - Elizabeth Lewis-Gray (METS), Peter Schutz (Food and Agribusiness) and Andrew Stevens (Advanced Manufacturing) - are respected industry leaders with extensive industry expertise and board expe... read more…

Nominations open soon for the 2015 Prime Minister's Prizes for Science

17 February 2015.   Help us recognise Australia’s best scientists and teachers, by nominating them for one of the Prime Minister’s Prizes for Science.   We’re looking for: The heroes of Australian science whose significant contribution to the advancement of knowledge through science deserves recognition; Exceptional innovators from science and industry who have enhanced our economy, ... read more…

BioMelbourne Network Women in Leadership Awards 2015

13 February 2015.  The BioMelbourne Network is very pleased to announce the launch of our inaugural “Women in Leadership” awards, to celebrate, honour and profile outstanding women in the biotechnology, medtech and healthcare technology sector. These new awards are designed to celebrate women who exhibit leadership in their fields of expertise and have made outstanding contributions to advan... read more…

Research Australia Congratulates New NHMRC CEO on Appointment

12 February 2015.  CEO arrives at a time of growth and opportunity in health and medical research.Research Australia welcomes today’s announcement by the Minister for Health, the Hon Sussan Ley, that Professor Anne Kelso AO has been appointed as the new Chief Executive Officer of the National Health and Medical Research Council (NHMRC). Research Australia CEO Elizabeth Foley said the depth of ... read more…

Spinifex Pharmaceuticals Enhances CMC Team with Two Senior Appointments

11 February 2015.  Spinifex Pharmaceuticals, a company focused on the development of new drugs for the treatment of chronic pain, today announces that it has enhanced its Chemistry, Manufacturing & Controls (CMC) capability as it continues to build the management team to drive the development of its lead candidate, EMA401, in a number of chronic pain indications. Dr Peter Spargo has joined Spin... read more…

Otifex - First Phase I Clinical Study Successfully Completed

10 February 2015.  Otifex Therapeutics, an emerging Australian specialty pharmaceutical company developing a new treatment for the most common cause of acquired hearing loss in childhood, Otitis Media with Effusion (OME or ‘glue ear’), has successfully completed the first stage of its clinical development programme. The Phase 1a study, conducted at two clinical sites in Australia, was a random... read more…

Gordagen Expands Corporate and Clinical Expertise as Enters Next Phase of Development

6 February 2015.  Gordagen Pharmaceuticals Pty. Ltd., a private company commercialising natural tocotrienols as evidence-based dietary supplements and pharmaceuticals, is pleased to announce the bolstering of its capacity through the appointment of senior executives and clinical expertise.Under guidance of the Board, Chaired by Mr Fred Nadjarian, former Managing Director of Roche Products, and ... read more…

Sienna Appoints Dr Cliff Holloway as Interim CEO

5 February 2015.  Sienna Cancer Diagnostics Ltd, a Melbourne-based biotechnology company, focused on developing novel in vitro diagnostics tests for cancer, has today announced that Dr Cliff Holloway has been appointed interim Chief Executive Officer. Dr Holloway will replace Dr Kerry Hegarty and commence work on February 2.Dr Holloway brings extensive experience to the role, having held execut... read more…

Smoking Hot - Invion (IVX) Ltd Morgan Climb Research

4 February 2015.  IVX has announced positive results in their interim data release for the phase II smoking cessation treatment IVN102. 4 major biomarkers were identified to have shown positive results. More recently IVX also announced that enrolment for IVN102 program has finished. The results will be released in the 1HCY15.Quarterly cash flow reportIVX has released its quarterly report noting... read more…

Gordagen Strengthens Global and Investment Ties through Board Appointment

3 February 2015.  Gordagen Pharmaceuticals Pty. Ltd., a biopharmaceutical company commercialising natural tocotrienols as evidence-based dietary supplements and pharmaceuticals, is pleased to announce the appointment of Mr Mohd Nasir bin Shafion (Nasir) to the Board of Directors.Mr Shafion is the CEO of Felda Wellness Corporation (FWC) in Malaysia. FWC is a botanical drug development company, t... read more…

Invion Completes Enrolment in its Phase II Trial of Oral INV102 (Nadolol) in Smoking Cessation

2 February 2015.  Invion Limited (ASX: IVX) is pleased to announce full enrolment in its phase II clinical trial of INV102 (nadolol) in patients with chronic cough or established COPD who are trying to quit smoking but have failed multiple times previously.Patients with chronic bronchitis or a smoker’s cough may have a harder time quitting smoking and are more likely to be incapacitated or die ... read more…

Circadian announces: US Patent Granted for Soluble VEGFR-3 Traps

28 January 2015.  Circadian Technologies Limited, through its wholly-owned subsidiary Vegenics Pty Ltd, is pleased to announce the grant of US Patent Number 8,940,695 on 27 January 2015. This US patent protects compositions containing soluble VEGFR-3 fusion proteins, such as OPT-302. Circadian is developing OPT-302 for the treatment of wet AMD (age-related macular degeneration) through its wh... read more…

Peter Lewis of Hydrix appointed a Member of the Order of Australia (AM) for services to ‘International Trade, Biotechnology and ICT’.

27 January 2015.  Peter Lewis, a high profile figure in the Australian biomedical devices industry was was appointed a Member of the Order of Australia (AM) on the 2015 Australia Day Honours list for his services to ‘International Trade, Biotechnology and ICT’. Mr Lewis is an accomplished senior executive with over 25 years’ experience leading growth strategies for technology based companies t... read more…

Sienna Readies for Next Phase of Growth - Chief Executive Officer Dr Kerry Hegarty to Step Down

22 January 2015.  Sienna Cancer Diagnostics Ltd, a Melbourne-based biotechnology company, focused on developing novel in vitro diagnostics tests for cancer, has today announced that Managing Director and Chief Executive Officer Dr Kerry Hegarty will step down from her position, after ten years in the role.Her resignation comes on the heels of recent transformational events for Sienna Cancer Dia... read more…

Murdoch Childrens-led mobile health APP, PEERSTM, a top 20 finalist in the OzAPP awards

20 January 2015.  Murdoch Childrens Research Institute has been named as a top 20 finalist in the 2014 – 15 OzAPP Awards for the development of a tablet-based app called PEERSTM. The OzAPP awards bring together the best mobile, web and cloud based app concepts in the Asia Pacific region. PEERSTM (Paediatric evaluation of emotions relationships and socialization) will be the first clinically-va... read more…

Invion Announces Positive Interim Data from its Phase II Clinical Trial of Oral INV102 (Nadolol) in Smoking Cessation

19 January 2015.  Invion Limited (ASX: IVX) is pleased to announce positive interim data from its phase II double-blind placebo-controlled randomised clinical trial in patients with chronic cough or established COPD who are trying to quit smoking but have failed multiple times previously. The interim data is generated from an assessment of sputum (phlegm) samples collected from patients upon r... read more…

Phosphagenics Appoints Dr Ross Murdoch as Chief Executive Officer

14 January 2015.  After an extensive global search, Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY) is pleased to announce the appointment of Dr Ross Murdoch as CEO. Dr Murdoch has more than 25 years of experience leading and managing the strategic, scientific and operational aspects of product research, development and commercialisation across the healthcare, ... read more…

Academia-industry Alliance Towards Autoimmune Disease

12 January 2015.   Monash University announced today that it has signed a research collaboration agreement with Janssen-Cilag Pty Ltd. (Janssen), one of the Janssen Pharmaceutical companies of Johnson & Johnson. The collaboration, facilitated by Johnson & Johnson Innovation, Asia Pacific, will focus on ground-breaking research at Monash University to develop potential new medicines to treat au... read more…

Melbourne Cancer Biotech Sienna Strikes First Big Deal with US Firm

8 January 2015.   Melbourne biotechnology start-up Sienna Cancer Diagnostics, which is backed by ex-Macquarie boss Allan Moss, has signed its first deal with an American pathology company paving the way for a potential float this year. The unlisted company, which was a beneficiary of the now defunct Commercialisation Australia grant program, will seek to raise $10 million. Chief executive Ke... read more…